$JBIO News

Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026

Wedbush Reiterates Outperform on Jade Biosciences, Maintains $47 Price Target

HC Wainwright & Co. Reiterates Buy on Jade Biosciences, Maintains $55 Price Target

Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis - Slideshow

Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis Transcript

Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026

Jade Biosciences, Inc. (JBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Jade Biosciences to Participate in Upcoming Conferences

Jade Biosciences: Duration Is The Real Product

Wedbush Maintains Outperform on Jade Biosciences, Raises Price Target to $47

Jade Biosciences Q2 EPS $(0.76) Misses $(0.64) Estimate

Jade Biosciences Enters Exclusive Worldwide License Agreement With Paragon Therapeutics; To Pay Up To $22M In Milestone Payments To Paragon; To Pay Paragon Low To Mid-Single-Digit Percentage Royalties On Net Sales Of Licensed Products; Paragon Barred From New Campaigns Targeting Licensed Target For At Least Five Years

Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market?

Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors

UBS Initiates Coverage On Jade Biosciences with Buy Rating, Announces Price Target of $45

Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Reported Earlier, Jade Biosciences Prices $150M Stock Offering Of 10M Shares at $15 Each

Jade Biosciences Announces Pricing of Public Offering of Common Stock

Jade Biosciences Announces Proposed Underwritten Public Offering

Jade Biosciences Reveals Proposed Underwritten Public Offering; No Size Disclosed